Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. According to the article, “HilleVax’s stock took a nosedive after the vaccine biotech’s sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE).” The article continues, “The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America.”
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
NVO | Novo Nordisk A/S | March 25, 2025 | Join |
GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
NEM | Newmont Corporation | April 01, 2025 | Join |
GSK | GSK plc | April 07, 2025 | Join |
NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
MRK | Merck & Co., Inc. | April 14, 2025 | Join |